FDA
-
-
-
-
-
-
-
Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps
-
-
-
-
-
-
-
Exact Sciences acquires exclusive license for Freenome blood-based CRC tests
-
-
-
-
-
-
-
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening
-
-
-
-
-
-
-
Exact Sciences (EXAS) PT Raised to $75 at BTIG
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Exact Sciences (EXAS)
-
-
-
-
-
-
-
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
-
-
-
-
-
-
-
Exact Sciences (EXAS) PT Lowered to $70 at BTIG
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

